Clinical Trial

Dapansutrile in Diabetes and Diabetes-Related Complications - Dapan-Dia

Study acronym: Dapan-Dia
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The aim of the study is to determine whether NLRP3 inhibition with dapansutrile represents a new pharmacological option for diabetes management with potential as an anti-inflammatory agent to also address micro- and macro-vascular risk and complications from diabetes.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2023-09-14; most recent amendment 2026-02-23.
Status change: Not Yet Recruiting → Recruiting 2024-07-02
Trial Details
NCT Number NCT06047262
Lead Sponsor Marc Donath
Collaborators: European Union, State Secretariat for Education Research and Innovation, Switzerland, Olatec Therapeutics, Inc., Departement Klinische Forschung Universität Basel, CTU Kantonsspital Baden
Conditions Diabetes Mellitus, Type 2
Enrollment 300 participants
Start Date 2024-07-09
Primary Completion 2028-07-31 (estimated)
Study Completion 2028-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-25